Outlook Therapeutics Inc (OTLK)
7.33
-0.10
(-1.35%)
USD |
NASDAQ |
May 16, 16:00
7.49
+0.16
(+2.18%)
After-Hours: 20:00
Outlook Therapeutics Research and Development Expense (Quarterly): 4.529M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.529M |
| September 30, 2023 | 4.944M |
| June 30, 2023 | 11.10M |
| March 31, 2023 | 0.5449M |
| December 31, 2022 | 9.862M |
| September 30, 2022 | 8.990M |
| June 30, 2022 | 11.25M |
| March 31, 2022 | 12.22M |
| December 31, 2021 | 9.872M |
| September 30, 2021 | 9.935M |
| June 30, 2021 | 8.545M |
| March 31, 2021 | 8.529M |
| December 31, 2020 | 11.95M |
| September 30, 2020 | 7.623M |
| June 30, 2020 | 8.488M |
| March 31, 2020 | 4.383M |
| December 31, 2019 | 5.847M |
| September 30, 2019 | 7.455M |
| June 30, 2019 | 4.342M |
| Date | Value |
|---|---|
| March 31, 2019 | 5.936M |
| December 31, 2018 | 6.072M |
| September 30, 2018 | 7.149M |
| June 30, 2018 | 5.796M |
| March 31, 2018 | 5.156M |
| December 31, 2017 | 0.4024M |
| September 30, 2017 | 2.305M |
| June 30, 2017 | 4.158M |
| March 31, 2017 | 4.117M |
| December 31, 2016 | 13.23M |
| September 30, 2016 | 3.873M |
| June 30, 2016 | 12.02M |
| March 31, 2016 | 4.138M |
| December 31, 2015 | 12.73M |
| September 30, 2015 | 13.20M |
| June 30, 2015 | 9.681M |
| March 31, 2015 | 10.15M |
| December 31, 2014 | 5.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.5449M
Minimum
Mar 2023
12.22M
Maximum
Mar 2022
7.916M
Average
8.529M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Cutera Inc | 5.001M |
| Actinium Pharmaceuticals Inc | 6.635M |
| GT Biopharma Inc | 1.357M |
| Karyopharm Therapeutics Inc | 35.42M |
| Marinus Pharmaceuticals Inc | 24.12M |